DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Quilizumab
Quilizumab
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
The Two Tontti Tudiul Lui Hi Ha Unit
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
Biologics in Asthma
Development of an Antibody That Neutralizes Soluble Ige and Eliminates Ige Expressing B Cells
First Preventive Mab for Hereditary Angioedema
Roche Group Development Pipeline
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
A Randomized Trial of the Efficacy and Safety of Quilizumab in Adults with Inadequately Controlled Allergic Asthma Jeffrey M
Hypersensitivity Reactions to Biologics (Part I): Allergy As an Important Differential Diagnosis in Complex Immune-Derived Adverse Events
(12) Patent Application Publication (10) Pub. No.: US 2016/0184445 A1 Perroth Et Al
(INN) for Biological and Biotechnological Substances
Roche Investor Day 2012 Workshop Gred
The Use of Biologics for Immune Modulation in Allergic Disease
Top View
Biologics in Asthma Are We Turning the Corner?
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
A61K9/51 (2006.01) — with International Search Report (Art
Redacted CSR Synopsis
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Asthma a Review of Medications, Quality Measures and Recommendations
(12) Patent Application Publication (10) Pub. No.: US 2017/0173267 A1 Ashmead Et Al
The Allergy, Genes and Environment (Allergen) Network 2004-2020
Five Computational Developability Guidelines for Therapeutic Antibody
Received: Jan 29, 2020 Revised: Mar 10, 2020 Accepted: Mar 13, 2020
Total Ige As a Marker for Chronic Spontaneous Urticaria
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
INN-Nimet 1 27.11.2018 a Abacavir Abacavirum Abakaviiri Abagovomab
Roche Pharma Research & Early Development) Gred (Genentech Research & Early Development)
The Therapeutic Antibody Profiler
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
CIC Investigators Test New Drug for Allergic Asthma
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
Novel Biologicals for the Treatment of Allergic Diseases and Asthma
QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
(INN) for Biological and Biotechnological Substances
WO 2015/036956 Al 19 March 2015 (19.03.2015) P O P C T
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
CAPTURE Study 2089
Tuning Ige: Ige-Associating Molecules and Their Effects on Ige-Dependent Mast Cell Reactions
Severe Asthma: Changing the Game a Supplement to CHEST Physician®
Anti-Ige for the Treatment of Chronic Urticaria
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
Hypersensitivity Reactions to Biologics (Part I)